Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial
Authors' conclusion
Treatment with the GLP-1 receptor agonist albiglutide resulted in a 25% relative risk reduction in MI that was consistent for type of infarction and presence or absence of ST elevation.
Study context
- Population
- Patients >40 years with T2DM and established atherosclerotic CVD
- Participants
- 9,463 patients
- Comparison
- Albiglutide vs placebo
- Primary endpoint
- Composite of:
- CV death
- MI
- Stroke (parent trial primary endpoint)
Methodological detailsevent-driven, multicentre, double-blind, placebo-controlled
- Event-driven
- Multicentre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
MI · median follow-up 1.6 years
Albiglutide vs PlaceboHazard ratio (CI)
First events
0.75(0.62–0.91)
Overall events
0.75(0.61–0.91)
- Patients with at least one myocardial infarction (MI) (overall)
- 421 (4.5%)
- Patients with more than one MI
- 72
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| MI by typeAlbiglutidevs PlaceboFirst type 1 MI | 0.73 (0.57–0.92) | |
| MI by typeAlbiglutidevs PlaceboFirst type 2 MI | 0.65 (0.46–0.92) | |
| STEMI and NSTEMIAlbiglutidevs PlaceboSTEMI | 0.69 (0.38–1.26) | |
| STEMI and NSTEMIAlbiglutidevs PlaceboNSTEMI | 0.86 (0.66–1.2) | |
| 0.20.5125Hazard ratio (log scale) |
STEMI and NSTEMI
- Effect consistent for STEMI and NSTEMI
Original publication
Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. Eur Heart J Cardiovasc Pharmacother. Published 25 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →